vectivbio ag is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. vectivbio was formed in 2019 as a spinout from therachon, a biotechnology company acquired by pfizer, inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. the company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in r&d, commercialization and business development for innovative products targeting orphan conditions with major unmet medical need. the company is drawing on the expertise of its founders as it continues to build a portfolio of rare disease medicines while advancing its lead program for short bowel syndrome.
Company profile
Ticker
VECT
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
VECT stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
24 Jul 23
EFFECT
Notice of effectiveness
24 Jul 23
EFFECT
Notice of effectiveness
24 Jul 23
EFFECT
Notice of effectiveness
24 Jul 23
POS AM
Prospectus update (post-effective amendment)
20 Jul 23
POS AM
Prospectus update (post-effective amendment)
20 Jul 23
POS AM
Prospectus update (post-effective amendment)
20 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 23
S-8 POS
Registration of securities for employees (post-effective amendment)
20 Jul 23
6-K
Current report (foreign)
17 Jul 23
Latest ownership filings
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 24
SC 13D
IRONWOOD PHARMACEUTICALS INC
7 Jul 23
SC 13G
Beryl Capital Management LLC
5 Jun 23
SC 13G/A
Novo Holdings A/S
26 May 23
SC 13D
ORBIMED ADVISORS LLC
24 May 23
SC 13G/A
ORBIMED ADVISORS LLC
14 Feb 23
SC 13G/A
Cormorant Asset Management, LP
14 Feb 23
SC 13G/A
EVENTIDE ASSET MANAGEMENT, LLC
14 Feb 23
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 23
SC 13G/A
CHI Advisors LLC
13 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 52 |
Opened positions | 44 |
Closed positions | 6 |
Increased positions | 2 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 399.72 bn |
Total shares | 103.75 mm |
Total puts | 18.00 k |
Total calls | 26.60 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
IRWD Ironwood Pharmaceuticals Inc - Ordinary Shares | 61.30 mm | $1.04 bn |
Orbimed Advisors | 5.16 mm | $87.66 bn |
Forbion Growth Opportunities Fund II Cooperatief U.A. | 5.13 mm | $40.88 mm |
Beryl Capital Management | 4.46 mm | $72.92 mm |
TCG Crossover Management | 3.11 mm | $52.93 bn |
Bpifrance Participations | 2.81 mm | $20.35 mm |
Versant Venture Capital V | 2.79 mm | $0.00 |
CHI Advisors | 2.78 mm | $46.95 bn |
Vivo Capital | 2.33 mm | $39.36 bn |
Glazer Capital | 1.88 mm | $31.88 mm |